Waterfront Wealth Inc. Purchases 60,798 Shares of Amarin Corporation PLC $AMRN

Waterfront Wealth Inc. lifted its position in shares of Amarin Corporation PLC (NASDAQ:AMRN) by 42.7% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 203,338 shares of the biopharmaceutical company’s stock after purchasing an additional 60,798 shares during the quarter. Waterfront Wealth Inc.’s holdings in Amarin were worth $2,940,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its stake in Amarin by 449,522.1% in the first quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company’s stock worth $815,000 after buying an additional 1,811,574 shares in the last quarter. Eversept Partners LP lifted its holdings in shares of Amarin by 2.9% in the 4th quarter. Eversept Partners LP now owns 172,188 shares of the biopharmaceutical company’s stock worth $2,403,000 after acquiring an additional 4,912 shares during the last quarter. Millennium Management LLC boosted its position in Amarin by 25.6% during the fourth quarter. Millennium Management LLC now owns 166,235 shares of the biopharmaceutical company’s stock valued at $2,320,000 after buying an additional 33,844 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Amarin by 15.0% during the third quarter. BNP Paribas Financial Markets now owns 87,366 shares of the biopharmaceutical company’s stock valued at $1,431,000 after buying an additional 11,425 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in shares of Amarin by 1.8% in the third quarter. Two Sigma Investments LP now owns 60,071 shares of the biopharmaceutical company’s stock worth $984,000 after buying an additional 1,047 shares during the period. Institutional investors own 22.25% of the company’s stock.

Amarin Price Performance

AMRN stock opened at $15.12 on Friday. The stock’s fifty day moving average price is $15.04 and its 200-day moving average price is $14.86. The company has a market cap of $317.07 million, a P/E ratio of -23.26 and a beta of 0.80. Amarin Corporation PLC has a 1 year low of $12.96 and a 1 year high of $20.90.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on AMRN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Amarin in a research note on Monday, April 20th. Zacks Research upgraded Amarin from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Amarin presently has a consensus rating of “Moderate Buy”.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.